TScan Therapeutics (TCRX) AI Stock Analysis

• Market Cap: $65.83M
• Dividend Yield: N/A
• Average Volume (3M): 894.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -42.94%
• EPS Growth: 12.25%
• Country: US
• Employees: 200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 52,471,405
• 10 Day Avg. Volume: 1,177,689
• 30 Day Avg. Volume: 894,032
• PEG Ratio: 0.17
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 120.90
• P/FCF Ratio: -2.97
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $6.25
• Price Target Upside: 438.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -1.25
• Revenue Forecast (FY): $9.91M

• Rating: 41 Neutral
• Price Target: $1.00 ▼(-13.79% Downside)

TScan Therapeutics faces significant financial challenges, with negative profitability and cash flow issues despite strong revenue growth. Technical analysis indicates bearish momentum, and valuation metrics reflect ongoing financial struggles. These factors contribute to a low overall stock score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for TScan's innovative therapies, suggesting potential for future market expansion and increased market share.

Gross Profit Margin

A high gross profit margin reflects effective cost control and pricing power, which can support sustainable profitability as the company scales.

Cash Flow Improvement

Improvement in free cash flow generation enhances TScan's ability to fund operations and invest in growth opportunities without relying heavily on external financing.

Negative Factors

Profitability Challenges

Ongoing profitability issues indicate operational inefficiencies and may hinder the company's ability to achieve sustainable financial health and shareholder returns.

Negative Return on Equity

A negative ROE suggests that TScan is not effectively utilizing shareholder capital to generate profits, which could impact investor confidence and future capital raising efforts.

Cash Flow Challenges

Significant cash flow challenges may limit TScan's ability to sustain operations and invest in R&D, potentially affecting long-term growth and innovation.

TScan Therapeutics Business Overview & Revenue Model

Company Description

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

TScan Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potentially through future sales of its therapeutic products once they receive regulatory approval. The company may enter into strategic partnerships with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of the products developed from these collaborations. Additionally, TScan may receive funding through grants and other financial support aimed at advancing its research initiatives.

TScan Therapeutics Financial Statement Overview

Summary

TScan Therapeutics is experiencing strong revenue growth, but profitability remains a significant challenge with negative margins across key metrics. The balance sheet shows a moderate level of leverage and a solid equity base, but the negative return on equity is concerning. Cash flow improvements are noted, yet the company faces ongoing cash flow difficulties. Overall, while there are positive growth indicators, the financial health is impacted by profitability and cash flow issues.

Income Statement

TScan Therapeutics shows a significant revenue growth rate of 57.45% in the TTM, indicating strong top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The high gross profit margin of 81.70% in the TTM suggests efficient cost management, but the overall negative margins highlight ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio of 0.36 in the TTM indicates a moderate level of leverage, which is manageable. However, the negative return on equity of -63.84% suggests that the company is not generating sufficient returns for its shareholders. The equity ratio of 59.19% reflects a solid capital structure, but the overall financial health is weakened by the negative profitability metrics.

Cash Flow

TScan Therapeutics has a positive free cash flow growth rate of 6.03% in the TTM, showing some improvement in cash generation. However, the operating cash flow to net income ratio of -4.03 indicates significant cash flow challenges. The free cash flow to net income ratio of 1.04 suggests that the company is generating slightly more free cash flow than net income, but the overall cash flow situation remains strained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.96M	2.82M	21.05M	13.54M	10.14M	1.08M
Gross Profit	6.25M	2.82M	-67.10M	8.40M	6.81M	-19.49M
EBITDA	-130.55M	-119.74M	-80.10M	-59.91M	-45.30M	-25.00M
Net Income	-136.78M	-127.50M	-89.22M	-65.81M	-48.63M	-26.02M
Balance Sheet
Total Assets	298.56M	371.12M	272.15M	199.09M	188.11M	49.74M
Cash, Cash Equivalents and Short-Term Investments	218.04M	290.11M	192.04M	120.03M	161.41M	34.79M
Total Debt	64.40M	97.38M	92.43M	85.98M	6.04M	7.43M
Total Liabilities	121.85M	130.15M	121.28M	99.66M	27.33M	92.20M
Stockholders Equity	176.71M	240.97M	150.87M	99.43M	160.78M	-42.46M
Cash Flow
Free Cash Flow	-131.25M	-114.65M	-64.50M	-70.73M	-58.62M	-7.26M
Operating Cash Flow	-126.18M	-110.82M	-61.36M	-66.50M	-48.68M	-3.02M
Investing Cash Flow	6.91M	-52.61M	-60.76M	-4.22M	-9.94M	-4.24M
Financing Cash Flow	46.51M	208.76M	135.44M	29.36M	189.67M	288.00K

TScan Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.95, below the 50-day MA of 1.91, and below the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 25.56 is Positive, neither overbought nor oversold. The STOCH value of 4.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRX.

TScan Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZNTL	46 Neutral	$93.78M	-0.56	-49.55%	―	-33.76%	17.10%
IKT	46 Neutral	$118.48M	-1.46	-97.49%	―	-100.00%	62.82%
SRZN	43 Neutral	$107.90M	-0.90	-130.27%	―	―	35.81%
TCRX	41 Neutral	$65.83M	―	-63.33%	―	-42.94%	12.25%
ALXO	39 Underperform	$78.18M	-0.66	-104.21%	―	―	39.60%
TIL	34 Underperform	$104.23M	―	-51.74%	―	―	29.72%

TScan Therapeutics Corporate Events

TScan Therapeutics Shifts Focus to Hematologic Malignancies

On November 3, 2025, TScan Therapeutics announced a strategic shift to prioritize its hematologic malignancies program, pausing enrollment in its solid tumor trial and focusing on preclinical efforts for solid tumors and autoimmunity target discovery. This decision, following a positive meeting with the FDA regarding the pivotal trial design for TSC-101, includes a 30% workforce reduction, aiming to save $45 million annually in 2026 and 2027, and extends the company’s cash runway into the second half of 2027.

The most recent analyst rating on (TCRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.

TScan Therapeutics’ Innovative Cancer Study: A Potential Game-Changer for Solid Tumors

Study Overview: TScan Therapeutics, Inc. is conducting a Phase 1 basket study titled A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors. The study aims to assess the safety and feasibility of T-Plex therapies in treating various solid tumors, particularly those associated with HPV. This research is significant as it explores personalized cellular therapies, potentially offering new treatment avenues for patients with advanced cancers.

TScan Therapeutics’ Long-Term Study: A Closer Look at TCR-T Therapies

Study Overview: TScan Therapeutics, Inc. is conducting a long-term follow-up study titled A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product. The study aims to monitor the long-term safety and efficacy of TSC-100 and TSC-101 TCR-T therapies in participants who previously received treatment in the TSCAN-001 study. This research is significant as it seeks to provide insights into the prolonged effects and safety of these innovative therapies for conditions like AML, ALL, and MDS.

TScan Therapeutics Advances Cancer Research with New Screening Study

Study Overview: TScan Therapeutics, Inc. is conducting a screening study titled Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors. The study aims to collect samples for HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and Tumor-associated Antigens (TAA) testing in patients with various metastatic solid tumors. The significance lies in determining eligibility for potential enrollment in further TScan clinical studies.

TScan Therapeutics’ Innovative Study on TSC-100 and TSC-101: A Potential Game-Changer in Leukemia Treatment

Study Overview: TScan Therapeutics, Inc. is conducting a clinical study titled A Controlled Multi-Arm Phase 1 Umbrella Study Evaluating the Safety and Feasibility of T-Cell Receptor Engineered Donor T-Cells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. The study aims to assess the safety, feasibility, and preliminary efficacy of TSC-100 and TSC-101 in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphoblastic leukemia (ALL) undergoing stem cell transplantation. This research is significant as it explores innovative treatments for these serious conditions.

TScan Therapeutics Updates Corporate Milestones and Strategies

On September 9, 2025, TScan Therapeutics released an updated corporate presentation outlining revised development and operational milestones, including adjusted timelines for its solid tumor program and updates on its pipeline for hematologic malignancies. The presentation, intended for investors and stakeholders, reflects the company’s ongoing efforts in target discovery initiatives in autoimmunity and highlights its strategic focus on advancing its TCR-T therapy candidates. This update is significant for stakeholders as it provides insights into TScan’s future growth strategies and its potential impact on the biotechnology industry.

The most recent analyst rating on (TCRX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.

TScan Therapeutics Reports Q2 2025 Financial Results

TScan Therapeutics, Inc. is a clinical-stage biotechnology company specializing in T cell receptor-engineered T cell therapies for cancer treatment, with a focus on hematologic malignancies and solid tumors. In its second quarter 2025 financial report, TScan Therapeutics highlighted significant advancements in its clinical programs, including the anticipated dosing of solid tumor patients with multiplex TCR-T therapies and the upcoming presentation of two-year relapse data from its ALLOHA Phase 1 trial. The company reported a substantial increase in revenue to $3.1 million, driven by its collaboration with Amgen, while research and development expenses rose to $32.6 million due to expanded manufacturing capabilities. Despite a net loss of $37 million, TScan maintains a strong cash position of $218 million, expected to fund operations into early 2027. Looking ahead, TScan aims to initiate a registrational trial for its lead candidate TSC-101 and file an IND for a new therapy, reflecting a strategic focus on advancing its pipeline and enhancing manufacturing efficiency.